Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
MDGN's Cash to Debt is ranked higher than
84% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. MDGN: No Debt )
MDGN' s 10-Year Cash to Debt Range
Min: 0.24   Max: No Debt
Current: No Debt

F-Score: 2
Z-Score: 9.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -92.98
MDGN's ROE (%) is ranked higher than
56% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. MDGN: -92.98 )
MDGN' s 10-Year ROE (%) Range
Min: -779.27   Max: -92.98
Current: -92.98

-779.27
-92.98
ROA (%) -74.19
MDGN's ROA (%) is ranked higher than
56% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. MDGN: -74.19 )
MDGN' s 10-Year ROA (%) Range
Min: -640.41   Max: -74.19
Current: -74.19

-640.41
-74.19
ROC (Joel Greenblatt) (%) -4991.04
MDGN's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. MDGN: -4991.04 )
MDGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4991.04   Max: -1215
Current: -4991.04

-4991.04
-1215
EBITDA Growth (%) 21.10
MDGN's EBITDA Growth (%) is ranked higher than
92% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. MDGN: 21.10 )
MDGN' s 10-Year EBITDA Growth (%) Range
Min: -17.5   Max: 184.4
Current: 21.1

-17.5
184.4
EPS Growth (%) 0.70
MDGN's EPS Growth (%) is ranked higher than
83% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. MDGN: 0.70 )
MDGN' s 10-Year EPS Growth (%) Range
Min: -12.7   Max: 167.8
Current: 0.7

-12.7
167.8
» MDGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MDGN Guru Trades in

Q1 2013

MDGN Guru Trades in Q1 2013

Jim Simons 26,300 sh (New)
» More
Q2 2013

MDGN Guru Trades in Q2 2013

Jim Simons 15,300 sh (-41.83%)
» More
Q3 2013

MDGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDGN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.20
MDGN's P/B is ranked higher than
64% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. MDGN: 9.20 )
MDGN' s 10-Year P/B Range
Min: 0   Max: 30.2
Current: 9.2

0
30.2
EV-to-EBIT -6.16
MDGN's EV-to-EBIT is ranked higher than
69% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDGN: -6.16 )
MDGN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -6.16

Current Ratio 7.36
MDGN's Current Ratio is ranked higher than
84% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. MDGN: 7.36 )
MDGN' s 10-Year Current Ratio Range
Min: 0.24   Max: 13.24
Current: 7.36

0.24
13.24
Quick Ratio 7.36
MDGN's Quick Ratio is ranked higher than
85% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. MDGN: 7.36 )
MDGN' s 10-Year Quick Ratio Range
Min: 0.24   Max: 13.24
Current: 7.36

0.24
13.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.50
MDGN's Price/Net Cash is ranked higher than
83% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. MDGN: 10.50 )
MDGN' s 10-Year Price/Net Cash Range
Min: 2.86   Max: 148.8
Current: 10.5

2.86
148.8
Price/Net Current Asset Value 9.90
MDGN's Price/Net Current Asset Value is ranked higher than
83% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. MDGN: 9.90 )
MDGN' s 10-Year Price/Net Current Asset Value Range
Min: 2.71   Max: 106.29
Current: 9.9

2.71
106.29
Price/Tangible Book 9.20
MDGN's Price/Tangible Book is ranked higher than
71% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. MDGN: 9.20 )
MDGN' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 105.4
Current: 9.2

2.6
105.4
Forward Rate of Return (Yacktman) -16.99
MDGN's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. MDGN: -16.99 )
MDGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -16.99

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MEDU.UK, MEDG.UK
Medgenics Inc was incorporated on 27th January 2000 in Delaware. The company is a medical technology and therapeutics company developing an innovative and proprietary platform technology offering. Its BiopumpTM Platform Technology converts a sliver of the patient's own dermal skin tissue into a protein-producing 'Biopump' to continuously produce and deliver therapeutic proteins. It is subject to the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations of the FDA, as well as to other federal, state, and local statutes and regulations.
» More Articles for MDGN

Headlines

Articles On GuruFocus.com
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 

More From Other Websites
MEDGENICS, INC. Financials Jul 22 2014
MEDGENICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jul 18 2014
MDGN: Trial / Development Timelines Remain On-Track Jul 17 2014
Medgenics Reports Second Quarter Financial Results Jul 16 2014
Medgenics Reports Second Quarter Financial Results Jul 16 2014
MEDGENICS, INC. Files SEC form 10-Q, Quarterly Report Jul 16 2014
Medgenics Announces Global Head, Research and Development, Garry Neil, M.D. Receives FDA... Jun 18 2014
Medgenics to Present at Two Upcoming Healthcare Investor Conferences Jun 16 2014
Medgenics Looking To Exploit Orphan Drug Market With Its Novel Biopump Protein Therapy Technology Jun 11 2014
Medgenics Announces First Patient Implanted in Phase 1/2 Clinical Trial of MDGN-201 (EPODURE) Jun 05 2014
MEDGENICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement May 21 2014
House Energy & Commerce Committee to hold a hearing May 20 2014
Medgenics Reports First Quarter Financial Results May 08 2014
MEDGENICS, INC. Files SEC form 10-Q, Quarterly Report May 08 2014
Medgenics awarded $2.2M grant from Israeli OCS Apr 15 2014
MEDGENICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... Apr 09 2014
Faruqi & Faruqi, LLP Launches An Investigation Against Medgenics, Inc. (MDGN) For Potential Breaches... Mar 14 2014
Medgenics, Inc. to Present at the 26th Annual ROTH Capital Growth Conference Mar 05 2014
Medgenics Reports 2013 Financial Results Feb 20 2014
MEDGENICS, INC. Files SEC form 10-K, Annual Report Feb 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide